The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
Open accessAbstract
Breast cancers often progress from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen- and chemotherapy-resistant phenotype with highly invasive and metastatic growth properties. This progression is usually accompanied by altered function of the estrogen receptor (ER) or outgrowth of ER-negative cancer cells. To understand the molecular mechanisms responsible for metastatic growth of ER-negative breast cancers, the activities of the transcription factor NF-kappaB (which modulates the expression of genes involved in cell proliferation, differentiation, apoptosis, and metastasis) were compared in ER-positive (MCF-7 and T47-D) and ER-negative (MDA-MB-231 and MDA-MB-435) human breast cancer cell lines. NF-kappaB, which is usually maintained in an inactive state by protein-protein interaction with inhibitor IkappaBs, was found to be constitutively active in ER-negative breast cancer cell lines. Constitutive DNA binding of NF-kappaB was also observed with extracts from ER-negative, poorly differentiated primary breast tumors. Progression of the rat mammary carcinoma cell line RM22-F5 from an ER-positive, nonmalignant phenotype (E phenotype) to an ER-negative, malignant phenotype (F phenotype) was also accompanied by constitutive activation of NF-kappaB. Analysis of individual subunits of NF-kappaB revealed that all ER-negative cell lines, including RM22-F5 cells of F phenotype, contain a unique 37-kDa protein which is antigenically related to the RelA subunit. Cell-type-specific differences in IkappaB alpha, -beta, and -gamma were also observed. In transient-transfection experiments, constitutive activity of an NF-kappaB-dependent promoter was observed in MDA-MB-231 and RM22-F5 cells of F phenotype, and this activity was efficiently repressed by cotransfected ER. Since ER inhibits the constitutive as well as inducible activation function of NF-kappaB in a dose-dependent manner, we propose that breast cancers that lack functional ER overexpress NF-kappaB-regulated genes. Furthermore, since recent data indicate that NF-kappaB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, our results provide an explanation for chemotherapeutic resistance in ER-negative breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Function and Activation of NF-kappaB in the Immune System
Baeuerle, P. A., & Henkel, T. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.001041 · Cited by 4,745
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Structure, Regulation and Function of NF-kappaB
Siebenlist, U., Franzoso, G., & Brown, K. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.002201 · Cited by 2,075
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Cited by
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Huber, M. A., Azoitei, N., Baumann, B., Grünert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., & Wirth, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421358 · Cited by 1,033
Frasor, J., Danes, J. M., Komm, B., Chang, K. C. N., Lyttle, C. R., & Katzenellenbogen, B. S. (2003) · Endocrinology · doi:10.1210/en.2003-0567 · Cited by 876
McKay, L. I., & Cidlowski, J. A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0375 · Cited by 805
Weaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis
Kucharczak, J., Simmons, M. J., Fan, Y., & Gélinas, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207230 · Cited by 769
Chen, F., Castranova, V., Shi, X., & Demers, L. M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.1.7 · Cited by 718
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Self-citationRoles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
Park, M., & Hong, J. (2016) · Cells · doi:10.3390/cells5020015 · Cited by 627
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., & Nakshatri, H. (2007) · Oncogene · doi:10.1038/sj.onc.1209808 · Cited by 596
Self-citationAggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., & Price, J. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1192 · Cited by 584
Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., & Fidler, I. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204535 · Cited by 556
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., & Karin, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00599-2 · Cited by 482
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203412 · Cited by 452
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Towne, J. E., Garka, K. E., Renshaw, B. R., Virca, G. D., & Sims, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400117200 · Cited by 419
Nuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
Role of Curcumin in Cancer Therapy
Shishodia, S., Chaturvedi, M. M., & Aggarwal, B. B. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.04.001 · Cited by 413
NF-κB as a primary regulator of the stress response
Mercurio, F., & Manning, A. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203174 · Cited by 411
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 399
NF-κB and cell-cycle regulation: the cyclin connection
JOYCE, D., ALBANESE, C., STEER, J., FU, M., BOUZAHZAH, B., & PESTELL, R. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00018-6 · Cited by 393
Transcription factor cross-talk: the estrogen receptor and NF-κB
Kalaitzidis, D., & Gilmore, T. D. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.01.004 · Cited by 388
p53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
NF‐κB and epithelial to mesenchymal transition of cancer
Min, C., Eddy, S. F., Sherr, D. H., & Sonenshein, G. E. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21695 · Cited by 376
The Rel/NF-κB family: friend and foe
Perkins, N. D. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01617-0 · Cited by 375
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.11.4079 · Cited by 367
Biswas, D. K., Cruz, A. P., Gansberger, E., & Pardee, A. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8542 · Cited by 351
Teixeira, J., Maheswaran, S., & Donahoe, P. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.5.0445 · Cited by 326
Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease
Jogie-Brahim, S., Feldman, D., & Oh, Y. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0028 · Cited by 323
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen
Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N., & Price, B. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203160 · Cited by 317
Caldas-Lopes, E., Cerchietti, L., Ahn, J. H., Clement, C. C., Robles, A. I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903392106 · Cited by 315
p53 stabilization is decreased upon NFκB activation
Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., & Verma, I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 313
Giri, D. K., & Aggarwal, B. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.14008 · Cited by 299
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Self-citationProtein kinase CK2 in mammary gland tumorigenesis
Landesman-Bollag, E., Romieu-Mourez, R., Song, D. H., Sonenshein, G. E., Cardiff, R. D., & Seldin, D. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204411 · Cited by 289
Joyce, D., Bouzahzah, B., Fu, M., Albanese, C., D'Amico, M., Steer, J., Klein, J. U., Lee, R. J., Segall, J. E., Westwick, J. K., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25245 · Cited by 287
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells
Gasparian, A. V., Yao, Y. J., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T. J., & Budunova, I. V. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.1.141 · Cited by 275
Nuclear factor-κB is upregulated in colorectal cancer
Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M., & MacKay, S. (2001) · Surgery · doi:10.1067/msy.2001.116672 · Cited by 269
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Molecular mechanisms of curcumin action: Gene expression
Shishodia, S. (2013) · BioFactors · doi:10.1002/biof.1041 · Cited by 263
Inflammation and Endometrial Cancer: A Hypothesis
Modugno, F., Ness, R. B., Chen, C., & Weiss, N. S. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0493 · Cited by 254
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2
Wang, X., Belguise, K., Kersual, N., Kirsch, K. H., Mineva, N. D., Galtier, F., Chalbos, D., & Sonenshein, G. E. (2007) · Nature Cell Biology · doi:10.1038/ncb1559 · Cited by 209
García-Rivera, D., Delgado, R., Bougarne, N., Haegeman, G., & Vanden Berghe, W. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.011 · Cited by 142
The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies
Schwartz, S. A., Hernandez, A., & Mark Evers, B. (1999) · Surgical Oncology · doi:10.1016/s0960-7404(00)00012-8 · Cited by 132
Nasu, K., Nishida, M., Kawano, Y., Tsuno, A., Abe, W., Yuge, A., Takai, N., & Narahara, H. (2011) · Reproductive Sciences · doi:10.1177/1933719110392059 · Cited by 73
Chen, X.-S., Wang, K.-S., Guo, W., Li, L.-Y., Yu, P., Sun, X.-Y., Wang, H.-Y., Guan, Y.-D., Tao, Y.-G., Ding, B.-N., et al. (2020) · Theranostics · doi:10.7150/thno.39814 · Cited by 58
Metadata
- Authors
- Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., & Sledge, G. W.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1997-07
- Volume
- 17
- Issue
- 7
- Pages
- 3629-3639
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2171865516
- Cited by
- 819
- References
- 61
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.